Skip to main content

Month: February 2021

Nykredit Realkredit A/S offentliggør tillæg nr. 2 til Basisprospekt af 13. maj 2020 – Nykredit Realkredit A/S

To Nasdaq Copenhagen11. februar 2021Nykredit Realkredit A/S offentliggør tillæg nr. 2 til Basisprospekt af 13. maj 2020Nykredit Realkredit A/S offentliggør tillæg nr. 2 til Basisprospekt af 13. maj 2020 for udbud af særligt dækkede obligationer, realkreditobligatiober og obligationer udstedt i medfør af § 15 i lov om realkreditlån og realkreditobligationer m.v.Nykredit Realkredit A/S’ Basisprospekt af 13. maj 2020 og tillæg er tilgængelige i elektronisk form på dansk og engelsk. Ved uoverensstemmelse mellem den danske og den engelske udgave er den danske udgave den gældende. Basisprospektet med tillæg kan ses på Nykredits hjemmeside nykredit.com/ir.Eventuelle spørgsmål kan rettes til Finansafdelingen, Head of Investor Relations Morten Bækmand Nielsen, telefon 44 55 15 21 eller advokat Kristian Ingemann Petersen, telefon 44 55 16...

Continue reading

Tree Island Steel to Issue Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (“Tree Island” or the “Company”) (TSX:TSL) is pleased to announce that it will report its fourth quarter and full year 2020 financial results for the period ended December 31, 2020, after market hours on Thursday, March 4, 2021.About Tree Island SteelTree Island Steel, headquartered in Richmond, British Columbia, since 1964, through its four operating facilities in Canada and the United States, produces wire products for a diverse range of industrial, residential construction, commercial construction and agricultural applications. Its products include galvanized wire, bright wire; a broad array of fasteners, including packaged, collated and bulk nails; stucco reinforcing products; concrete reinforcing mesh; fencing and other fabricated wire products....

Continue reading

CanWel Building Materials to Issue Fourth Quarter and Full Year 2020 Financial Results March 11, 2021

NOT FOR RELEASE OR DISSEMINATION INTO THE UNITED STATESVANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) — CanWel Building Materials Group Ltd. (“CanWel” or “the Company”) (TSX:CWX, CWX.NT.A) is pleased to announce that it will report its fourth quarter and full year 2020 financial results for the period ended December 31, 2020, after market hours on March 11, 2021.The Company will host an analyst call the following day, Friday, March 12, 2021 at 11:00 am ET. Amar Doman, Chairman of the Board and Chief Executive Officer, and James Code, Chief Financial Officer, will discuss the Company’s financial performance for the period ended December 31, 2020.To access the call, please dial 1-866-548-4713 or 1-323-794-2093. A replay of the conference call will be available from 2:00 pm ET on March 12, 2021, until 11:59 pm ET, March...

Continue reading

7GC & Co. Holdings Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing February 12, 2021

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) — 7GC & Co. Holdings Inc. (NASDAQ: VIIAU) (the “Company”) announced that, commencing February 12, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “VII” and “VIIAW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “VIIAU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order...

Continue reading

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

MONMOUTH JUNCTION, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat retinal diseases (NORSE THREE).Two of the three planned clinical trials for the ONS-5010 / LYTENAVA™ wet age-related macular degeneration (wet AMD) U.S. Biologics License Application (BLA) are now completed. The open-label safety study enrolled 197 subjects, in only 4 weeks, with a range of retinal diseases for which an anti-VEGF drug is a therapeutic option, including wet AMD, diabetic macular edema (DME)...

Continue reading

Biogen Announces the Expiration Date Results of Its Cash Tender Offer

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”).The Cash Offer expired at 5:00 p.m., New York City time, on February 10, 2021 (the “Expiration Date”). The “Settlement Date” will be promptly following the Expiration Date and is expected...

Continue reading

ABM Supports ASM Global for a Healthy Return to Sports and Entertainment Facilities

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, announced today it has joined forces with ASM Global (ASM), the world’s leading venue management and services company, and other partners, to execute on ASM’s industry-leading VenueShield program. VenueShield is a comprehensive set of protocols and procedures that provide trusted protection for the live experience, based on critical healthcare insights and partnerships with leading sports and entertainment facility experts. The program will support the continued reopening of more than 325 ASM venues and client partners worldwide. The deal was brokered by AEG Global Partnerships.“We’re proud to have the opportunity to leverage our expertise and solutions to help ASM enhance and scale their VenueShield reopening protocols,” said Billy...

Continue reading

Aleafia Health Launches Sunday Market™ House of Brands

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of its new Canadian cannabis portfolio Sunday MarketTM. Under the Sunday Market family are four new distinct brands, each tailored to a specific consumer segment and featuring its own roster of cannabis products.The four brands will be launched in the adult-use market, with some formats also being made available to patients of Aleafia Health’s medical cannabis subsidiary, Emblem. They will complement Aleafia Health’s existing Symbl adult-use brand and Kin Slips sublingual strips line of products.“The Sunday Market house of brands has been crafted to provide consumers with a welcoming, authentic experience that showcases the local community and the people that create great cannabis...

Continue reading

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million provides funding to advance the R&D pipelineAnnounced confirmatory Phase 3 AFFIRM-AL study of birtamimab in Mayo Stage IV patients with AL amyloidosis under SPA agreement with FDA at p≤0.10Reported significantly reduced decline in motor function in Phase 2 study of prasinezumab in Parkinson’s diseaseReported improvements in neuropathy and cardiac function in Phase 1 study of PRX004 in ATTR amyloidosisDUBLIN, Ireland, Feb. 11, 2021 (GLOBE NEWSWIRE) — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid...

Continue reading

Genocea Provides Fourth Quarter 2020 Corporate Update

GEN-011 and GEN-009 clinical trials continue to advanceATLASTMstimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer DiscoveryAnnouncing SARS-CoV-2 T cell antigen discovery programConference call today at 8:30 a.m. E.T.CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2020 and other recent significant developments.“We are extremely pleased to make progress across multiple fronts by using ATLAS’ unique ability to find the most relevant targets of T cell responses,” said Chip Clark, Genocea President and Chief Executive Officer. “As we advance GEN-009 and GEN-011, our scientific team continues to refine...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.